ASTRAZENECA PHARMA INDIA Financial Statement Analysis
|
||
|
The Revenues of ASTRAZENECA PHARMA INDIA have increased by 32.48% YoY .
The Earnings Per Share (EPS) of ASTRAZENECA PHARMA INDIA has decreased by -28.33 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
ASTRAZENECA PHARMA INDIA Last 5 Annual Financial Results
[BOM: 506820|NSE : ASTRAZEN]
| Standalone | Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 |
|---|---|---|---|---|---|
| Revenues | ₹1,716 Cr | ₹1,296 Cr | ₹1,003 Cr | ₹806 Cr | ₹814 Cr |
| Expenses | ₹1,462 Cr | ₹1,111 Cr | ₹838 Cr | ₹719 Cr | ₹678 Cr |
| Operating Profit (Excl OI) | ₹254 Cr | ₹184 Cr | ₹165 Cr | ₹86 Cr | ₹135 Cr |
| Other Income | ₹41 Cr | ₹35 Cr | ₹26 Cr | ₹15 Cr | ₹13 Cr |
| Interest | ₹1.46 Cr | ₹1.20 Cr | ₹0.63 Cr | ₹0.95 Cr | ₹1.09 Cr |
| Depreciation | ₹40 Cr | ₹15 Cr | ₹16 Cr | ₹17 Cr | ₹20 Cr |
| Profit Before Tax | ₹156 Cr | ₹220 Cr | ₹134 Cr | ₹83 Cr | ₹127 Cr |
| Profit After Tax | ₹116 Cr | ₹162 Cr | ₹99 Cr | ₹62 Cr | ₹93 Cr |
| Earnings Per Share (Rs) | ₹46.30 | ₹64.60 | ₹39.72 | ₹24.64 | ₹37.32 |
| PAT Margin (%) | 6.72 | 12.40 | 9.85 | 7.61 | 11.42 |
| ROE(%) | 15.73 | 24.95 | 18.13 | 12.78 | 22.83 |
| ROCE(%) | 21.29 | 33.94 | 24.49 | 17.36 | 31.24 |
| Total Debt/Equity(x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Key Financials |
||
| Market Cap | : | ₹ 22,081.6 Cr |
| Revenue (TTM) | : | ₹ 1,716.3 Cr |
| Net Profit(TTM) | : | ₹ 115.7 Cr |
| EPS (TTM) | : | ₹ 46.3 |
| P/E (TTM) | : | 190.8 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| ASTRAZENECA PHARMA INDIA | -3.2% | 1.1% | 27.5% |
| SUN PHARMACEUTICAL INDUSTRIES | 0.4% | 1.8% | 4.5% |
| DIVIS LABORATORIES | -1.1% | 0.1% | 45.6% |
| CIPLA | 3.8% | 1.2% | -1.1% |
| TORRENT PHARMACEUTICALS | 2.2% | 11.7% | 11.7% |
| DR REDDYS LABORATORIES | 1.4% | -3.3% | -7.2% |
| MANKIND PHARMA | -1.7% | 13% | 22.9% |
| ZYDUS LIFESCIENCES | 0.7% | -0.6% | -17.7% |
| LUPIN | 1.5% | 1.3% | 7% |
ASTRAZENECA PHARMA INDIA Revenues
[BOM: 506820|NSE : ASTRAZEN]
| Y-o-Y | 32.48 % |
| 5 Yr CAGR | 20.52 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2025 | ₹1,716 Cr | 32.48 | |
| Mar2024 | ₹1,296 Cr | 29.17 | |
| Mar2023 | ₹1,003 Cr | 24.50 | |
| Mar2022 | ₹806 Cr | -0.98 | |
| Mar2021 | ₹814 Cr | - | |
ASTRAZENECA PHARMA INDIA Operating Profit
[BOM: 506820|NSE : ASTRAZEN]
| Y-o-Y | 37.69 % |
| 5 Yr CAGR | 17.01 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2025 | ₹254 Cr | 37.69 | |
| Mar2024 | ₹184 Cr | 11.71 | |
| Mar2023 | ₹165 Cr | 91.60 | |
| Mar2022 | ₹86 Cr | -36.38 | |
| Mar2021 | ₹135 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 3.93 % |
| 5 Yr CAGR | -2.90 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2025 | 14.8% | 3.93 | |
| Mar2024 | 14.24% | -13.49 | |
| Mar2023 | 16.46% | 53.83 | |
| Mar2022 | 10.7% | -35.74 | |
| Mar2021 | 16.65% | - | |
ASTRAZENECA PHARMA INDIA Profit After Tax
[BOM: 506820|NSE : ASTRAZEN]
| Y-o-Y | -28.34 % |
| 5 Yr CAGR | 5.54 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2025 | ₹116 Cr | -28.34 | |
| Mar2024 | ₹162 Cr | 62.66 | |
| Mar2023 | ₹99 Cr | 61.19 | |
| Mar2022 | ₹62 Cr | -33.98 | |
| Mar2021 | ₹93 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -45.81 % |
| 5 Yr CAGR | -12.42 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2025 | 6.72 % | -45.81 | |
| Mar2024 | 12.4 % | 25.89 | |
| Mar2023 | 9.85 % | 29.43 | |
| Mar2022 | 7.61 % | -33.36 | |
| Mar2021 | 11.42 % | - | |
ASTRAZENECA PHARMA INDIA Earnings Per Share (EPS)
[BOM: 506820|NSE : ASTRAZEN]
| Y-o-Y | -28.33 % |
| 5 Yr CAGR | 5.54 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2025 | ₹46 | -28.33 | |
| Mar2024 | ₹65 | 62.64 | |
| Mar2023 | ₹40 | 61.20 | |
| Mar2022 | ₹25 | -33.98 | |
| Mar2021 | ₹37 | - | |
ASTRAZENECA PHARMA INDIA Return on Capital Employed (ROCE)
[BOM: 506820|NSE : ASTRAZEN]
| Y-o-Y | -37.27 % |
| 5 Yr CAGR | -9.14 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2025 | 21.29% | -37.27 | |
| Mar2024 | 33.94% | 38.59 | |
| Mar2023 | 24.49% | 41.07 | |
| Mar2022 | 17.36% | -44.43 | |
| Mar2021 | 31.24% | - | |
ASTRAZENECA PHARMA INDIA Share Price vs Sensex
| Current Share Price | : | ₹8,832.7 |
| Current MarketCap | : | ₹ 22,081.6 Cr |
| Updated EOD on | : | Jul 25,2025 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ASTRAZENECA PHARMA INDIA | -3.2% |
1.1% |
27.5% |
| SENSEX | -0.4% |
-1.6% |
1.3% |
ASTRAZENECA PHARMA INDIA related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE ALLCAP | 6.4% | 8.9% | 7.5% |
| BSE MIDSMALLCAP | 4.7% | 9% | 8.4% |
| BSE 500 SHARIAH | 4.3% | 4.3% | 1.1% |
| BSE HEALTHCARE | 0.5% | 4% | 17% |
| BSE 500 | -1.1% | -1.1% | 0% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY 500 | -1.1% | -1.2% | 0.7% |
| NIFTY TOTAL MARKET | -1.2% | -1.2% | 0.7% |
| NIFTY500 MULTICAP 50:25:25 | -1.5% | -1% | 1.2% |
| NIFTY500 LARGEMIDSMALL EQUAL-CAP WEIGHTED INDEX | -1.8% | -0.9% | 1.5% |
| NIFTY500 SHARIAH | -2.1% | -1.5% | -8.7% |
You may also like the below Video Courses
FAQ about ASTRAZENECA PHARMA INDIA Financials
How the annual revenues of ASTRAZENECA PHARMA INDIA have changed ?
The Revenues of ASTRAZENECA PHARMA INDIA have increased by 32.48% YoY .
How the Earnings per Share (EPS) of ASTRAZENECA PHARMA INDIA have changed?
The Earnings Per Share (EPS) of ASTRAZENECA PHARMA INDIA has decreased by -28.33 % YoY .
Check out Intrinsic Value of Peers of ASTRAZENECA PHARMA INDIA
Compare Stock Analytics of Peers of ASTRAZENECA PHARMA INDIA
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
